Ask AI

Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs

Gain more insights into the clinical role of TROP-2–directed ADCs in the management of patients with HER2-negative metastatic breast cancer, and learn how to individualize treatment in the sequencing of these agents and optimal management of the associated adverse events through a certified on-demand webcast, expert commentary, and downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.